Dr. Paul Sax discusses the newest drug approved for the treatment of HIV and how it fits into the current therapeutic landscape.

How do we balance the need for certain lab tests with the overriding requirement to protect the public? Paul Auwaerter, MD, offers his opinion on this complex topic.

Dr. Paul Sax considers what we know and don't know about the use of stem cell transplantation in eradicating HIV, as presented at IAS 2013.

Dr. Sandra Fryhofer talks about the changes in screening recommendations for HIV from the US Preventive Services Task Force.

Is the nation on the verge of a healthcare provider shortage, or are clinicians being phased out by algorithms?

Dr. Paul Sax reviews the most recent data and guidance on the use of preexposure prophylaxis in the prevention of HIV acquisition.

Some doctors don't want to drain terminally ill patients of any hope for recovery. Others say it's wise to let patients know of their prognosis so that they can make the necessary arrangements.

Can the clinician and the statistician be friends? Andrew Vickers argues that they must work together more closely in order to conduct reliable, useful research that improves patient care.

Dr. Paul Sax considers the effects of halting the HVTN 505 study on the future of HIV vaccine research.

Dr. Paul Sax looks at how 2 new drugs for hepatitis C could -- if approved -- change the treatment paradigm for patients with HIV/HCV coinfection.